FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 253 filers reported holding FATE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.41 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $244 | -45.9% | 51,350 | -35.1% | 0.02% | -42.4% |
| Q1 2023 | $451 | +99.6% | 79,137 | +254.0% | 0.03% | +73.7% |
| Q4 2022 | $226 | -99.9% | 22,356 | +31.9% | 0.02% | -45.7% |
| Q3 2022 | $380,000 | -30.7% | 16,952 | -23.3% | 0.04% | -30.0% |
| Q2 2022 | $548,000 | +76.8% | 22,103 | +176.4% | 0.05% | +400.0% |
| Q1 2022 | $310,000 | +50.5% | 7,996 | +126.6% | 0.01% | +42.9% |
| Q4 2021 | $206,000 | – | 3,528 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 569,889 | $51,820,000 | 67.63% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,379,064 | $307,258,000 | 39.62% |
| Darwin Global Management, Ltd. | 952,847 | $86,642,000 | 24.18% |
| Redmile Group, LLC | 12,629,737 | $1,148,422,000 | 13.91% |
| DAFNA Capital Management LLC | 334,360 | $30,403,000 | 9.05% |
| Casdin Capital, LLC | 3,050,000 | $277,337,000 | 8.22% |
| Grosvenor Holdings, L.L.C. | 1,459,517 | $132,714,000 | 7.23% |
| Copernicus Capital Management, LLC | 3,240 | $295,000 | 4.60% |
| Eversept Partners, LP | 399,499 | $36,326,444 | 4.26% |
| Ally Bridge Group (NY) LLC | 260,000 | $23,642,000 | 4.05% |